• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Articles by Michael Fitzhugh

FDA OKs Astrazeneca's Fasenra for severe eosinophilic asthma patients

Nov. 16, 2017
By Michael Fitzhugh
Astrazeneca plc has won FDA approval to market Fasenra (benralizumab) as an add-on maintenance therapy for severe, eosinophilic asthma patients, age 12 years and older. Injected every eight weeks after a run-in period, the monoclonal antibody helped trial patients achieve a reduction in their annual asthma exacerbation rates (AAER) of up to 51 percent vs. placebo.
Read More

Loxo Oncology lands Bayer deal for TRK inhibitors valued at up to $1.55B

Nov. 15, 2017
By Michael Fitzhugh
Loxo Oncology Inc. wasn't actively seeking a partner for its two most advanced contenders for the treatment of a rare type of genetically defined cancer but, given the opportunity to nail down a potential $1.55 billion deal with Bayer AG, "we saw the financial and strategic rationale," Jacob Van Naarden, Loxo's chief business officer, told BioWorld.
Read More

Can a pill tackle type 1 diabetes? IM Therapeutics looks to find out

Nov. 9, 2017
By Michael Fitzhugh
Immunomolecular (IM) Therapeutics LLC, a company created to develop small-molecule therapies for the treatment of genetically defined autoimmune diseases, has revealed its lead candidate, an immunotherapy for type 1 diabetes, IMT-002. The molecule, a proprietary formulation of the D enantiomer of methyldopa, already has FDA orphan status and could enter phase I testing next year after the company files an investigational new drug application (IND) in the second quarter of 2018.
Read More

Pique’s PT-107 extends median OS in phase II NSCLC trial

Nov. 8, 2017
By Michael Fitzhugh
An allogeneic whole cell vaccine for the treatment of non-small-cell lung cancer (NSCLC) developed by Pique Therapeutics Inc. helped people with late-stage, second-line disease achieve a median overall survival (OS) of 12.5 months during a phase II trial, an improvement of 4.1 months over the median OS of patients who received placebo. For the 71 nonsquamous patients enrolled in the study, median OS extended to 15.5 months, besting median OS in the placebo arm by nearly 10 months.
Read More

Medco kicks off critical pivotal inclisiran program

Nov. 7, 2017
By Michael Fitzhugh
Patient dosing has begun in the first of four pivotal trials key to The Medicines Co.'s big bet on inclisiran, a cardiovascular-focused RNAi therapy critical to the drugmaker's return to profitability.
Read More

Boehringer seals $201M Dicerna deal targeting NASH and other liver diseases

Nov. 3, 2017
By Michael Fitzhugh
Boehringer Ingelheim GmbH is enlisting early stage RNAi specialist Dicerna Pharmaceuticals Inc. to discover and develop new therapies for chronic liver diseases, starting with nonalcoholic steatohepatitis (NASH).
Read More

Bluebird brightens Lentiglobin outlook with protocol, manufacturing changes

Nov. 2, 2017
By Michael Fitzhugh
Bluebird Bio Inc. reported that new data from an ongoing phase I trial of its gene therapy, Lentiglobin, in sickle cell disease suggests that changes made to the study protocol and to manufacturing of the therapy are improving engraftment of the gene-modified stem cells. After trading as high as $161.84, company shares (NASDAQ:BLUE) ended the day Wednesday at $142.95, up $3.85, as the company detailed its third-quarter earnings and previewed clinical data it plans to present at the American Society of Hematology (ASH) meeting next month.
Read More

Amgen buys out JV partner Kirin Holdings in $780M deal

Nov. 1, 2017
By Michael Fitzhugh
After more than three decades of joint adventure for Japan's Kirin Holdings Co. Ltd. (KHK) and Thousand Oaks, Calif.-based Amgen Inc., the partners are winding down a JV with a $780 million payout to redeem the Asian conglomerate's shares in the business, Kirin-Amgen Inc. The business will now become a wholly owned subsidiary of Amgen. KHK said that it will continue to develop, manufacture and sell pharmaceuticals licensed by Kirin-Amgen.
Read More

Novartis tenders $3.9B offer for radiotherapy maker Advanced Accelerator Applications

Oct. 31, 2017
By Michael Fitzhugh

Novartis tenders $3.9B offer for radiotherapy maker Advanced Accelerator Applications

Oct. 31, 2017
By Michael Fitzhugh
Novartis AG has proposed buying radiopharmaceuticals specialist Advanced Accelerator Applications SA (AAA) in a deal valuing the company at $3.9 billion. The transaction would add the EU-approved neuroendocrine tumor therapy Lutathera (lutetium [177Lu] oxodotreotide) to the company's portfolio, as well as a new technology platform that Novartis said has potential applications across a number of early oncology development programs.
Read More
Previous 1 2 … 98 99 100 101 102 103 104 105 106 … 179 180 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe